Réglementaire - Sciences de la Vie

Dernier

• You're currently reading page 1
• Page 2
• Page 3
• Page 4
• Page 5
• Page 6
• Page 7
• …
• Page 23
• Page 24
• Suiv.: Page >

• Towards a legislative framework for Patient Support Programmes (PSP’s) in Belgium

  Article

  Envoyé: 29 May 2018

  In the past years, the Federal Agency for Medicines and Health Products (FAMHP) recorded an increase in the use of Patient Support Programmes (PSP’s) in Belgium.

• Newsflash - Adoption en 1ère lecture d'une proposition de loi réformant la procédure de choix des CPP (Comités de Protection des Personnes) chargés d'évaluer les essais cliniques

  Article

  Envoyé: 25 May 2018

  Le 17 mai 2018, l'Assemblée nationale a adopté, en première lecture, une proposition de loi réformant la procédure de choix des CPP (Comités de Protection des Personnes) chargés d'évaluer les essais cliniques.

• Dispositif « anti-cadeaux » : un industriel et deux pharmaciens condamnés

  Article

  Envoyé: 25 May 2018

  Le Tribunal correctionnel de Lons-le-Saulnier a condamné, le 7 novembre 2017, deux pharmaciens et une société commercialisant des médicaments génériques pour violation de la réglementation anti-cadeaux.

• Importance of registering exclusive licence to recover full costs

  Article

  Envoyé: 24 May 2018

  The importance of registering an exclusive licence was underlined in a recent High Court decision, where the claimant exclusive licensee was deducted 35% of its costs in successful infringement proceedings for failure to register an exclusive licence.

• New FAMHP Financing Act: impact on the medtech industry

  Article

  Envoyé: 23 May 2018

  A Belgian Act of 11 March 2018 (the Financing Act) has recently made changes to financial organisation of the Belgian Federal Agency for Medicines and Health Products (FAMHP), with several implications for the medical devices industry.

• Licence to terminate? Repudiation and practical issues to consider when terminating a patent licence

  Article

  Envoyé: 15 May 2018

  This article discusses the issues that licensors need to consider when terminating a patent licence, as well as the practical implications resulting from termination of such licence.

• Orphan drug exclusivity: case law update

  Article

  Envoyé: 19 April 2018

  In this article, we recap on the earlier Teva v EMA decision and summarise the recent outcome in Shire v EMA. We have also included relevant parts of the Regulation 141/2000 on Orphan Medicinal Products in the Annex hereto.

• Sunshine Act: Last-minute checklist ahead of the deadline

  Article

  Envoyé: 13 April 2018

  The final date to upload transparency reports on www.betransparent.be is Thursday 31 May 2018. Ahead of this final date, we prepared a checklist with practical action points to consider ahead of the deadline.

• Artificial Intelligence: the key French priority

  Article

  Envoyé: 03 April 2018

  The French report on artificial intelligence (AI) was finally released this Thursday, 29 March 2018. The mission who issued the report (also named “Villani’s” report after its leader, Cédric Villani, French Member of the National Assembly, Fields medal laureate 2010), was commissioned by the French Government in September 2017 to consider the French strategy for artificial intelligence (AI).

• You're currently reading page 1
• Page 2
• Page 3
• Page 4
• Page 5
• Page 6
• Page 7
• …
• Page 23
• Page 24
• Suiv.: Page >